Generic Name and Formulations:
Calcitonin-salmon (rDNA origin) 200 IU/spray; nasal spray.
Various generic manufacturers
- Liquid Biopsy May Help Predict Survival in Medullary Thyroid Carcinoma
- Bortezomib and Thalidomide Associated with Pulmonary Function Abnormalities in Myeloma Patients
- Altered Pancreatic Innervation Linked to Changes in Pain-Related Behavior
Indications for Calcitonin-salmon:
Limitations Of use:
Not shown to increase BMD in early postmenopausal women.
1 spray (200Units) in alternating nostrils daily.
Correct hypocalcemia and other disorders (eg, Vit. D deficiency) prior to initiating; monitor serum calcium during therapy. Supplement diet with calcium (1g/day) and Vit. D (400 IU/day); reevaluate periodically. Seizures. Do periodic nasal exams; discontinue if severe nasal ulceration occurs. Increased risk of malignancies. Pregnancy (Cat.C), nursing mothers: not recommended.
May antagonize lithium; adjust dose.
Rhinitis, epistaxis, other nasal symptoms, back pain, arthralgia, headache; hypersensitivity reactions, antibody formation.
Formerly known under the brand name Fortical or Miacalcin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC